Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
MD.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
MK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
MK.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LZ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LZ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
MB.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
MB.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.3.2.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.3.2.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.50NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.50NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.2.14NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.2.14NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
unclassifiableNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
unclassifiableNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KS.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KS.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HH.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HH.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XCENUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCENUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HN.4.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HN.4.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GU.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GU.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LP.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LP.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.3.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
KP.3.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KP.3.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.3.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
LF.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LF.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.16NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.16NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BR.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BR.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CH.1.1.28NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CH.1.1.28NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CH.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CH.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.7.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used